Fate Therapeutics (FATE) Tops Q4 EPS by 28c

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.58), $0.28 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $44.34 million versus the consensus estimate of $17.88 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Snail, Inc. (SNAL) Reports Q3 Loss of $0.36
• Black Rock Coffee Bar, Inc. (BRCB) Misses Q2 EPS by 1c